AI assistant
BOTANIX PHARMACEUTICALS LTD — Director's Dealing 2020
May 10, 2020
64551_rns_2020-05-10_6f457e0a-328a-4246-804f-d0a99e9c069a.pdf
Director's Dealing
Open in viewerOpens in your device viewer
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Botanix Pharmaceuticals Limited ABN 70 009 109 755
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director | Dr Michael Thurn |
|---|---|
| Date of last notice | 10 December 2019 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | Direct and Indirect |
|---|---|
| Nature of indirect interest(including registered holder)Note: Provide details of the circumstancesgiving rise to the relevant interest. | Dr Thurn is the trustee of the Thurn Family Trust |
| Date of change | 8 May 2020 |
| No. of securities held prior tochangeMichael Joseph ThurnMichael Joseph Thurn | 200,000 Ordinary Shares5,000,000 Unlisted Options expiring on 18/07/2023 exercisable at$0.2512,346,497 Ordinary Shares2,882,837 Unlisted Options expiring on 08/05/2020 exercisable at$0.072,000,000 Unlisted Options expiring on 05/12/2021 exercisable at$0.106 |
| Class | Unlisted Options |
| Number acquired | - |
| Number disposed | 2,882,837 Unlisted Options |
|---|---|
| Value/ConsiderationNote: If consideration is non-cash, providedetails and estimated valuation | Nil |
| No. of securities held after changeMichael Joseph ThurnMichael Joseph Thurn | 200,000 Ordinary Shares5,000,000 Unlisted Options expiring on 18/07/2023 exercisable at$0.2512,346,497 Ordinary Shares2,000,000 Unlisted Options expiring on 05/12/2021 exercisable at$0.106 |
| Nature of changeExample: on-market trade, off-market trade,exercise of options, issue of securities underdividend reinvestment plan, participation inbuy-back | Expiry of Unlisted Options |
Part 2 – Change of director’s interests in contracts – N/A
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| thispart. | |
|---|---|
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder(if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuation | N/A |
| Interest after change | N/A |
Part 3 –[+] Closed period
| Interest after changeN/Aart 3 –+Closed period | |
|---|---|
| Were the interests in the securities or contracts detailed abovetraded during a+closed period where prior written clearancewas required? | No |
| If so, was prior written clearance provided to allow the trade toproceed during this period? | N/A |
| If prior written clearance was provided, on what date was thisprovided? | N/A |